Barker finds Peace at Aegate after Noon
This article was originally published in Scrip
Drug authentication company Aegate has appointed Michael Peace CEO, following the departure of Gary Noon. Mr Peace joins Aegate from Thomson Reuters, where he was head of Asia for the financial markets business, the global head of the research and asset management division at Reuters and CEO of Lipper, a Thomson Reuters company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.